Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories (NYSE:ABT) is down 1.7% to trade at $107.79 at last glance, despite the company's strong second-quarter earnings and revenue, both of which beat estimates.

Abbot Laboratories Stock Lower on Disappointing Forecast

Abbott Laboratories (ABT) stock is falling on Wednesday despite posting a positive earnings report for the second quarter of 2022. The post Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Beat appeared first on InvestorPlace.

Abbott Laboratories (ABT) Stock Slides Despite Q2 Earnings Beat

Abbott Laboratories (NYSE:ABT ) Q2 2022 Earnings Conference Call July 20, 2022 9:00 AM ET Company Participants Scott Leinenweber - Vice President, Investor Relations, Licensing & Acquisition Robert Ford - Chairman & Chief Executive Officer Bob Funck - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Joshua Jennings - Cowen Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Jayson Bedford - Raymond James Operator Good morning and thank you for standing by. Welcome to Abbott's Second Quarter 2022 Earnings Conference Call.

Abbott Laboratories (ABT) CEO Robert Ford on Q2 2022 Results - Earnings Call Transcript

Abbott Laboratories (NYSE: ABT) has reported Q2 FY22 adjusted EPS of $1.43, up 22.2% Y/Y, better than the consensus of $1.12. Q2 sales of $11.3 billion increased 10.1% on a reported basis and 14.3% on an organic basis, beating the consensus of $10.29 billion.

Abbott Lifts Annual Profit Guidance On Higher COVID-19 Test Sales

Abbott Laboratories (NYSE: ABT) shares are trading lower Wednesday after the company reported financial results. Abbott said second-quarter revenue increased 10.1% year-over-year to $11.3 billion, which beat the estimate of $10.29 billion, according to data from Benzinga Pro.

What's Going On With Abbott Stock Today?

Shares of Abbott Laboratories ABT, +2.72% fell 2.85% to $106.8 in premarket trading Wednesday although the company beat second-quarter earnings and sales estimates, fueled by sales of its COVID-19 tests. In the second quarter of 2022 Abbott reported earnings of $2.018 billion, or $1.14 per share, compared to earnings of $1.189 billion, or 66 cents a share, in the same period last year.

Abbott Laboratories shares fall in premarket despite second-quarter earnings beat

Abbott Laboratories on Wednesday topped estimates for second-quarter sales and earnings and guided higher for the full year. The post Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings appeared first on Investor's Business Daily.

Abbott Laboratories Posts Better-Than-Expected Q2 Sales, Earnings

Abbott reports revenue of $11.3 billion for the quarter, up 10.1% from the same quarter last year.

Abbott Raises Guidance After Posting Earnings Beat. The Stock Is Rising.

Abbott Laboratories on Wednesday raised its annual earnings forecast following strong demand for its medical devices and diagnostics products.

Abbott raises 2022 profit forecast

Sales growth of 10.1 percent; organic sales growth of 14.3 percent GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent Global COVID-19 testing-related sales of $2.3 billion in the second quarter Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022.

Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

Intuitive Surgical

Moderna

These players are trading at bargain prices today.

3 Healthcare Stocks That Could Help Set You Up for Life

AbbVie

Johnson & Johnson

Recession or no recession, these well-established businesses are going to keep on growing.

3 Dividend Growth Stocks You Can Buy Now and Hold Forever

ASML Hld

Baker Hughes Co

Netflix

Omnicom Group

The three major U.S. equity indexes closed higher on Friday. The Dow Jones industrials gained 2.2%, the S&P 500 added 1.9% and the Nasdaq rose by 1.8%.

Earnings Previews: Abbott Labs, ASML, Baker Hughes, Netflix, Omnicom

Diversified global medical science products maker Abbott (NYSE: ABT) stock is down a modest (-11.5%) on the year. Abbott provides full lifecycle health and medical products from baby formula to nutrition supplement products, chronic disease treatments and medical devices to generic pharmaceuticals

Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio

NEW YORK--(BUSINESS WIRE)-- #ABT--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) on behalf of Abbott stockholders. Our investigation concerns whether Abbott has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or misl

ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Abbott Stockholders and Encourages Investors to Contact the Firm

3 Dividend Growth Stocks to Buy in July

Amgen

Air Products and Chemicals

Blackrock Inc

Home Depot

Mastercard

NIKE

Texas Instruments

Union Pacific

Visa

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.

10 Dividend Growth Stocks For July 2022

Pfizer

UnitedHealth Group

Health and wealth; it doesn't get much better than that.

Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever

Abbott Laboratories said on Friday it expects to begin releasing EleCare formula next week from its recently reopened Sturgis plant, which has been at the center of a baby formula shortage in the United States.

Abbott expects to start shipping EleCare infant formula next week

A rise in the number of procedures performed will likely aid the company's medical devices sales, offsetting any decline in the diagnostics business, given that the segment benefited from higher Covid-19 testing in the prior-year quarter.

Will Abbott Stock Rise After Its Q2 Results?

H.B. Fuller

Lowe's

Altria

MSA Safety

Parker-Hannifin

PPG Industries

Stanley Black & Decker

Sysco

Target

Tennant

The 44 Dividend Kings finished June in the red, collectively losing 5.39%. Last month, the 11 best dividend kings based on forecasted growth and valuation underperformed the average dividend king return by 152 bps.

My 11 Best Dividend Kings For July 2022

Attractive returns should be on the way for these companies' shareholders.

2 Top Healthcare Stocks to Buy and Hold for the Long Haul

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Abbott (ABT) Q2 Earnings Expected to Decline

Federal Realty Investment Trust

Kimberly-Clark

PepsiCo

Dividend Kings are usually looked at as a safer bet than other investments because it gives you stable income during market volatility. The post 5 Dividend Kings That Income Investors Can Count On appeared first on InvestorPlace.

5 Dividend Kings That Income Investors Can Count On

Abbott (NYSE: ABT) announced that the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), which is a form of major depressive disorder (MDD). These are the details.

News for Abbott Labs Stock (ABT)